Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Deferred Revenue (2018)

Anika Therapeutics (ANIK) has disclosed Current Deferred Revenue for 7 consecutive years, with $52000.0 as the latest value for Q3 2018.

  • Quarterly Current Deferred Revenue changed N/A to $52000.0 in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $52000.0 through Sep 2018, changed N/A year-over-year, with the annual reading at $24510.0 for FY2014, 98.9% down from the prior year.
  • Current Deferred Revenue for Q3 2018 was $52000.0 at Anika Therapeutics, down from $74000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $139535.0 in Q1 2015, with the low at $12885.0 in Q3 2014.
  • Average Current Deferred Revenue over 3 years is $48299.0, with a median of $35938.0 recorded in 2015.
  • The sharpest move saw Current Deferred Revenue tumbled 98.99% in 2014, then skyrocketed 200.64% in 2015.
  • Over 3 years, Current Deferred Revenue stood at $24510.0 in 2014, then surged by 38.51% to $33948.0 in 2015, then surged by 53.18% to $52000.0 in 2018.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $52000.0, $74000.0, and $33948.0 for Q3 2018, Q2 2018, and Q3 2015 respectively.